Role of Serum Ca and 1,25(OH)2D3 as Predictor in Bone Metabolism Abnormality by Chronic Medication of Anticonvulsant

ABSTRACT

PURPOSE: Chronic use of anticonvulsant bring about abnormalities of bone metabolism, as hypocalcemia, rickets and osteomalacia. Early detection and treatment of abnormalities is important to pediatric patients. To investigate the usefulness of the serum Ca and 1,25(OH)2D3 as an predictor of bone metabolism abnormality, the study was done. METHODS: Serum Ca, P, ALP and 1,25(OH)2D3 were measured and analyzed in 48 children who diagnosed as convulsive disorder and took anticonvulsant medication over 6 months in Pediatric Department of Kyung Hee Medical Center. RESULTS: 1) Average duration of medication was 3.4+/-2.5yrs. 2) Values of serum Ca and P, ALP, 1,25(OH)2D3 were normal. 3) Serum levels of anticonvulsants were therapeutic range. 4) 1,25(OH)2D3 had significant correlation to serum Ca (P<0.005) and P (P<0.05) but no correlation to ALP. 5) Duration of medication had significant correlation to 1,25(OH)2D3 (P<0.05) but no correlation to Ca. 6) Duration of medication had no correlation to 1,25(OH)2D3 and Ca. CONCLUSIONS: Because 1,25(OH)2D3 is a good predictor for change of bone metabolism by chronic medication of anticonvulsant than Ca, its regular check is necessary.